Xencor (XNCR) Competitors $8.30 +0.23 (+2.85%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$8.34 +0.04 (+0.48%) As of 07/2/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. BHC, GMTX, APLS, ARWR, VCEL, TWST, KNSA, RXRX, DNLI, and NAMSShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), Twist Bioscience (TWST), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Vericel Twist Bioscience Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Denali Therapeutics NewAmsterdam Pharma Bausch Health Cos (NYSE:BHC) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do institutionals & insiders have more ownership in BHC or XNCR? 78.7% of Bausch Health Cos shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, BHC or XNCR? Bausch Health Cos has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Is BHC or XNCR more profitable? Bausch Health Cos has a net margin of -0.41% compared to Xencor's net margin of -181.17%. Xencor's return on equity of -31.94% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos-0.41% -540.45% 5.26% Xencor -181.17%-31.94%-22.19% Which has better valuation and earnings, BHC or XNCR? Bausch Health Cos has higher revenue and earnings than Xencor. Bausch Health Cos is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.63B0.27-$46M-$0.11-64.64Xencor$110.49M5.35-$232.62M-$3.06-2.71 Do analysts prefer BHC or XNCR? Bausch Health Cos currently has a consensus price target of $7.42, indicating a potential upside of 4.31%. Xencor has a consensus price target of $28.00, indicating a potential upside of 237.35%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor BHC or XNCR? In the previous week, Bausch Health Cos had 8 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Bausch Health Cos and 2 mentions for Xencor. Xencor's average media sentiment score of 0.94 beat Bausch Health Cos' score of 0.61 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBausch Health Cos and Xencor tied by winning 8 of the 16 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$574.35M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-2.718.8326.1719.90Price / Sales5.35663.86413.55113.66Price / CashN/A151.5836.1356.90Price / Book0.864.548.025.38Net Income-$232.62M$31.16M$3.15B$248.50M7 Day Performance-1.19%0.07%1.48%2.06%1 Month Performance-9.19%7.24%3.66%4.86%1 Year Performance-55.40%1.37%34.68%20.24% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor4.0503 of 5 stars$8.30+2.9%$28.00+237.3%-54.5%$574.35M$110.49M-2.71280BHCBausch Health Cos3.2418 of 5 stars$6.11-1.1%$7.42+21.4%+0.0%$2.29B$9.63B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5337 of 5 stars$17.62-0.4%$40.05+127.3%-49.1%$2.22B$781.37M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9354 of 5 stars$15.51+1.2%$43.71+181.8%-33.0%$2.12B$3.55M-11.08400Positive NewsVCELVericel2.8889 of 5 stars$41.80-0.5%$61.14+46.3%-8.0%$2.12B$237.22M1,393.80300TWSTTwist Bioscience4.4187 of 5 stars$35.33+2.0%$50.40+42.7%-20.4%$2.08B$312.97M-10.87990News CoveragePositive NewsKNSAKiniksa Pharmaceuticals International3.7148 of 5 stars$28.72+1.0%$38.80+35.1%+48.7%$2.08B$423.24M-114.88220RXRXRecursion Pharmaceuticals1.8974 of 5 stars$4.83-4.0%$7.00+44.9%-27.2%$2.04B$58.84M-2.73400DNLIDenali Therapeutics4.5657 of 5 stars$13.62-1.9%$33.71+147.5%-31.5%$2.02B$330.53M-5.10430NAMSNewAmsterdam Pharma2.9978 of 5 stars$18.21+1.4%$42.89+135.5%-6.6%$2.02B$45.56M-9.694 Related Companies and Tools Related Companies Bausch Health Cos Alternatives Gemini Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Vericel Alternatives Twist Bioscience Alternatives Kiniksa Pharmaceuticals International Alternatives Recursion Pharmaceuticals Alternatives Denali Therapeutics Alternatives NewAmsterdam Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
